{
    "clinical_study": {
        "@rank": "89201", 
        "arm_group": [
            {
                "arm_group_label": "Dapsone Gel Subset 1", 
                "arm_group_type": "Experimental", 
                "description": "Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours."
            }, 
            {
                "arm_group_label": "Dapsone Gel Subset 2", 
                "arm_group_type": "Experimental", 
                "description": "Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine the cumulative irritation potential and sensitization potential of\n      dapsone gel and vehicle after repeat applications on the skin of healthy volunteers."
        }, 
        "brief_title": "Dermal Tolerability of Dapsone Gel in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Healthy adults.\n\n        Exclusion Criteria:\n\n          -  Skin diseases, excessive hair, tattoos, pigmentation, scars or moles that could\n             interfere with patch application\n\n          -  Sensitivity to adhesive bandages or tape."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117752", 
            "org_study_id": "225678-009"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dapsone Gel Subset 1", 
                    "Dapsone Gel Subset 2"
                ], 
                "description": "Patches containing dapsone gel will be applied to the skin.", 
                "intervention_name": "dapsone gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dapsone Gel Subset 1", 
                    "Dapsone Gel Subset 2"
                ], 
                "description": "Patches containing dapsone gel vehicle will be applied to the skin.", 
                "intervention_name": "dapsone gel vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dapsone Gel Subset 1", 
                "description": "Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.", 
                "intervention_name": "sodium lauryl sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dapsone Gel Subset 1", 
                    "Dapsone Gel Subset 2"
                ], 
                "description": "Patches containing normal saline (Negative Control) will be applied to the skin.", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dapsone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Paramus", 
                    "country": "United States", 
                    "state": "New Jersey"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Mean Cumulative Irritation Index During Induction Phase", 
                "safety_issue": "No", 
                "time_frame": "21 Days"
            }, 
            {
                "measure": "Incidence of Sensitization Reactions During Challenge Phase", 
                "safety_issue": "No", 
                "time_frame": "6 Weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117752"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}